Gaucher's disease

(redirected from Gaucher's)
Also found in: Dictionary, Medical, Encyclopedia.
Related to Gaucher's: Gaucher's cells
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to Gaucher's disease

a rare chronic disorder of lipid metabolism of genetic origin

References in periodicals archive ?
The corresponding substrates are then accumulated.[sup][1] The overall incidence rate of these diseases was approximately 1:5000.[sup][2] Gaucher's disease (GD) includes several clinical subtypes with a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type.
Prior Authorization Criteria For Use of Injectable/Oral Medication in the Treatment of Gaucher's disease, August 16, 2001, UMC-530-0011.
The NGF also would like to impress on the public that having Gaucher's disease is no longer a death sentence as there are currently many options, tools, treatments and programs available for those with the disease.
This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Gynecologic and obstetric aspects of Gaucher's disease: a survey of 53 patients.
Nisman et al., "Cytokines in Gaucher's disease," European Cytokine Network, vol.
* A snapshot of the global therapeutic scenario for Gaucher's Disease.
Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy.
London, May 10 (ANI): Scientists at The Scripps Research Institute have shed light on a mechanism that enables a potential treatment for Gaucher's disease and other lysosomal storage diseases.
<![CDATA[ An Israeli firm has passed the first hurdle in gaining FDA approval for a new treatment for Gaucher's disease.]]>
9 December 2009 - Israeli biopharmaceutical company Protalix BioTherapeutics Inc (AMEX: PLX) said today it has completed its New Drug Application (NDA) submission with the US Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's disease.